Crushing disappointment is fairly common in biotech and tends to be the end-game for many stories, but every once in a while there are companies that rebound from major disappointment and go on to considerable success. Not only does Neurocrine Biosciences (NBIX) look like one such story, but the potential of these shares is such that even a conservative analysis can make an investor do a double-take.
From Bedtime To Women's Health
I owned Neurocrine years ago and profited greatly from the run-up on anticipation of the company's success with indiplon - a insomnia drug that the company developed and eventually partnered with Pfizer (PFE). I sold out a bit before the peak, and the stock was subsequently crushed as the FDA refused to approve indiplon and Pfizer killed the partnership.
Please read more here:
Neurocrine Could Be A Major Biotech Comeback Story
No comments:
Post a Comment